Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma Identifying Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma

What this Trial Is About

Researchers are studying glioblastomas, the most common and aggressive brain tumors in adults, which often return despite standard surgery and chemoradiotherapy treatments. This observational study aims to better understand the changes in gene activity, proteins, and metabolism in tumors that have relapsed compared to the original tumors. The goal is to find new markers that can predict outcomes and identify potential targets for future treatments. The study involves patients who had surgery for both their initial and relapsed glioblastoma tumors between 2005 and 2023 at the University Hospital of Bordeaux. Researchers will analyze paired tumor samples collected during these surgeries to examine metabolic, genomic, and proteomic features. This retrospective analysis focuses on how these characteristics relate to patient survival after relapse. Participants' tumor samples will be studied to evaluate metabolic changes involved in glioblastoma relapse over up to two years. Secondary outcomes include monitoring progression-free survival and overall survival for up to five years after the second surgery. The study relies on existing surgical samples and patient data, with no new treatment administered, and participation involves no additional interventions beyond sample analysis.

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma